Shahzeb Khan

Shahzeb Khan

Auto-generated profile, based on publicly available information

Shahzeb Khan

Centre for Biotechnology and Microbiology, University of Swat, Swat, Khyber Pakhtunkhwa, Pakistan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MKMazhar Khan
Mazhar Khan
SKShahzeb Khan
Shahzeb Khan
AAAsim Ali
Asim Ali
HAHameed Akbar
Hameed Akbar
ASAbrar Mohammad Sayaf
Abrar Mohammad Sayaf
DWDong-Qing Wei
Dong-Qing Wei
Helicobacter Pyloriis a known causal agent of gastric malignancies and peptic ulcers. The extremophile nature of this bacterium is protecting it from designing a potent drug against it. Therefore, the use of computational approaches to design antigenic, stable and safe vaccine against this pathogen could help to control the infections associated with it. Therefore, in this study, we used multiple immunoinformatics approaches along with other computational approaches to design a multi-epitopes subunit vaccine againstH.Pylori. A total of 7 CTL and 12 HTL antigenic epitopes based on c-terminal cleavage and MHC binding scores were predicted from the four selected proteins (CagA, OipA, GroEL and cagA). The predicted epitopes were joined by AYY and GPGPG linkers. Β-defensins adjuvant was added to the N-terminus of the vaccine. For validation, immunogenicity, allergenicity and physiochemical analysis were conducted. The designed vaccine is likely antigenic in nature and produced robust and substantial interactions with Toll-like receptors (TLR-2, 4, 5, and 9). The vaccine developed was also subjected to anin silicocloning and immune response prediction model, which verified its efficiency of expression and the immune system provoking response. These analyses indicate that the suggested vaccine may produce particular immune responses againstH. pylori, but laboratory validation is needed to verify the safety and immunogenicity status of the suggested vaccine design.